Stryker (SYK) Shows ‘Muscle’ at Investor Day, but Truist Stays Neutral

On November 14, Truist’s expert Richard Newitter boosted the terms people connected Stryker Corporation (NYSE:SYK) to $400 from $392 and maintained a Hold standing connected the stock. The expert noted that the company’s Investor Day stressed its presumption arsenic 1 of the stronger large-cap MedTech names with ‘muscle’, with the quality to present dependable operating leverage each year. That said, the steadfast is maintaining a neutral stance for now, highlighting its penchant for companies with dependable gross maturation and faster earnings.

In its net for the 3rd 4th of 2025, Stryker Corporation (NYSE:SYK)’s absorption noted the company’s committedness to borderline enlargement and beardown show contempt tariff headwinds. The company’s gross for the 4th was $6.1 billion, which grew by implicit 10% from the aforesaid play past year. Its integrated income roseate by 9.5%, which included 9.1% from accrued portion measurement and 0.4% from higher prices. The institution present expects integrated nett income maturation of 9.8% to 10.2%.

In summation to beardown net growth, Stryker Corporation (NYSE:SYK)’s 32-year dividend maturation streak is besides appealing to income investors. Moreover, the payout ratio of astir 43% indicated aboriginal dividend growth.

Stryker Corporation (NYSE:SYK) is simply a aesculapian exertion institution that manufactures and markets a wide scope of products and services.

While we admit the imaginable of SYK arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 High Quality Dividend Stocks for Long-Term Investors and 15 Dividend Stocks That Outperform the S&P 500

Disclosure: None.